ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

Y-90 Radioembolization Stabilizes Liver Metastases in 98.5 Percent Of Breast Cancer Patients in Study

March 28, 2014

NCI’s Richard Kaplan named associate director, National Cancer Research Network of UK.

January 2, 2004

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

Clinical Oncology Grant Funding: The History Of a Controversy

July 23, 1993

FDA Issues Final Rules On Patient Access To Investigational Drugs

September 11, 2009

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

April 29, 1988